blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1999148

EP1999148 - HUMANIZED ANTI-CD22 ANTIBODIES AND THEIR USE IN TREATMENT OF ONCOLOGY, TRANSPLANTATION AND AUTOIMMUNE DISEASE [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  31.10.2014
Database last updated on 22.08.2024
Most recent event   Tooltip15.07.2016Lapse of the patent in a contracting state
New state(s): TR		published on 17.08.2016  [2016/33]
Applicant(s)For all designated states
MedImmune, LLC
One MedImmune Way
Gaithersburg, MD 20878 / US
[2014/04]
Former [2013/52]For all designated states
Aeres Biomedical Limited
1-3 Burtonhole Lane, Mill Hill
London NW7 1AD / GB
Former [2008/50]For all designated states
Aeres Biomedical Limited
1-3 Burtonhole Lane, Mill Hill
London NW7 1AD / GB
Inventor(s)01 / JONES, Tarran
1 Christchurch Crescent
Radlett
Hertforshire WD7 8AG / GB
02 / WILLIAMS, David, G.
56 White Horse Drive
Epsom
Surrey KT18 7LY / GB
 [2013/52]
Former [2008/50]01 / JONES, Tarran
1 Christchurch Crescent Radlett
Hertforshire WD7 8AG / GB
02 / WILLIAMS, David, G.
56 White Horse Drive Epsom
Surrey KT18 7LY / GB
Representative(s)Gibbs, Richard
Marks & Clerk LLP The Beacon
176 St Vincent Street
Glasgow G2 5SG / GB
[N/P]
Former [2013/44]Gibbs, Richard
Marks & Clerk LLP Aurora 120 Bothwell Street
Glasgow G2 7JS / GB
Former [2008/50]Weber, Martin, et al
Jones Day Prinzregentenstrasse 11
80538 München / DE
Application number, filing date07752572.306.03.2007
[2008/50]
WO2007US05883
Priority number, dateUS20060779804P06.03.2006         Original published format: US 779804 P
[2008/50]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2007103469
Date:13.09.2007
Language:EN
[2007/37]
Type: A2 Application without search report 
No.:EP1999148
Date:10.12.2008
Language:EN
The application published by WIPO in one of the EPO official languages on 13.09.2007 takes the place of the publication of the European patent application.
[2008/50]
Type: B1 Patent specification 
No.:EP1999148
Date:25.12.2013
Language:EN
[2013/52]
Type: B8 Corrected title page of specification 
No.:EP1999148
Date:05.03.2014
[2014/10]
Search report(s)International search report - published on:US16.10.2008
(Supplementary) European search report - dispatched on:EP15.04.2010
ClassificationIPC:C07K16/00, C12P21/08, C07K1/00, C07K16/28, C07K16/46, A61K39/395, A61P35/00
[2010/19]
CPC:
C07K16/2803 (EP,US); C07K16/2851 (US); A61P35/00 (EP);
A61P37/00 (EP); A61P37/06 (EP); C07K16/465 (EP,US);
A61K2039/505 (EP,US); C07K2317/24 (EP,US); C07K2317/565 (EP,US);
C07K2317/567 (EP,US); C07K2317/732 (EP,US); C07K2317/734 (EP,US);
C07K2317/77 (EP,US); C07K2317/92 (EP,US) (-)
Former IPC [2008/50]C07K16/00, C12P21/08, C07K1/00
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2008/50]
Extension statesAL02.10.2008
BA02.10.2008
HR02.10.2008
MK02.10.2008
RS02.10.2008
TitleGerman:HUMANISIERTE ANTI-CD22-ANTIKÖRPER UND IHRE VERWENDUNG FÜR DIE BEHANDLUNG VON KREBS, TRANSPLANTATIONEN UND AUTOIMMUNERKRANKUNGEN[2008/50]
English:HUMANIZED ANTI-CD22 ANTIBODIES AND THEIR USE IN TREATMENT OF ONCOLOGY, TRANSPLANTATION AND AUTOIMMUNE DISEASE[2008/50]
French:ANTICORPS HUMANISÉS DIRIGÉS CONTRE L'ANTIGÈNE CD22 ET LEUR UTILISATION À DES FINS THÉRAPEUTIQUES EN ONCOLOGIE, AINSI QUE DANS LE CADRE DE TRANSPLANTATIONS ET DE MALADIES AUTO-IMMUNES[2013/31]
Former [2008/50]ANTICORPS ANTI-CD22 HUMANISÉS ET LEUR UTILISATION DANS UN TRAITEMENT ONCOLOGIQUE, D'UNE TRANSPLANTATION ET D'UNE MALADIE AUTO-IMMUNE
Entry into regional phase02.10.2008National basic fee paid 
02.10.2008Search fee paid 
02.10.2008Designation fee(s) paid 
02.10.2008Examination fee paid 
Examination procedure02.10.2008Examination requested  [2008/50]
08.12.2008Amendment by applicant (claims and/or description)
13.07.2010Despatch of a communication from the examining division (Time limit: M06)
24.01.2011Reply to a communication from the examining division
06.06.2011Despatch of a communication from the examining division (Time limit: M06)
15.12.2011Reply to a communication from the examining division
09.07.2012Despatch of a communication from the examining division (Time limit: M06)
18.01.2013Reply to a communication from the examining division
18.07.2013Communication of intention to grant the patent
11.11.2013Fee for grant paid
11.11.2013Fee for publishing/printing paid
Divisional application(s)EP12175725.6  / EP2540741
EP13170804.2  / EP2650306
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  13.07.2010
Opposition(s)26.09.2014No opposition filed within time limit [2014/49]
Fees paidRenewal fee
13.03.2009Renewal fee patent year 03
15.03.2010Renewal fee patent year 04
15.03.2011Renewal fee patent year 05
14.03.2012Renewal fee patent year 06
11.03.2013Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU06.03.2007
AT25.12.2013
BE25.12.2013
BG25.12.2013
CY25.12.2013
CZ25.12.2013
DK25.12.2013
EE25.12.2013
ES25.12.2013
FI25.12.2013
IT25.12.2013
LT25.12.2013
LV25.12.2013
MC25.12.2013
MT25.12.2013
NL25.12.2013
PL25.12.2013
RO25.12.2013
SE25.12.2013
SI25.12.2013
SK25.12.2013
TR25.12.2013
LU06.03.2014
GR26.03.2014
CH31.03.2014
LI31.03.2014
IS25.04.2014
PT28.04.2014
[2016/33]
Former [2016/32]HU06.03.2007
AT25.12.2013
BE25.12.2013
BG25.12.2013
CY25.12.2013
CZ25.12.2013
DK25.12.2013
EE25.12.2013
ES25.12.2013
FI25.12.2013
IT25.12.2013
LT25.12.2013
LV25.12.2013
MC25.12.2013
MT25.12.2013
NL25.12.2013
PL25.12.2013
RO25.12.2013
SE25.12.2013
SI25.12.2013
SK25.12.2013
LU06.03.2014
GR26.03.2014
CH31.03.2014
LI31.03.2014
IS25.04.2014
PT28.04.2014
Former [2016/29]AT25.12.2013
BE25.12.2013
BG25.12.2013
CY25.12.2013
CZ25.12.2013
DK25.12.2013
EE25.12.2013
ES25.12.2013
FI25.12.2013
IT25.12.2013
LT25.12.2013
LV25.12.2013
MC25.12.2013
MT25.12.2013
NL25.12.2013
PL25.12.2013
RO25.12.2013
SE25.12.2013
SI25.12.2013
SK25.12.2013
LU06.03.2014
GR26.03.2014
CH31.03.2014
LI31.03.2014
IS25.04.2014
PT28.04.2014
Former [2016/28]AT25.12.2013
BE25.12.2013
BG25.12.2013
CY25.12.2013
CZ25.12.2013
DK25.12.2013
EE25.12.2013
ES25.12.2013
FI25.12.2013
LT25.12.2013
LV25.12.2013
MC25.12.2013
MT25.12.2013
NL25.12.2013
PL25.12.2013
RO25.12.2013
SE25.12.2013
SI25.12.2013
SK25.12.2013
LU06.03.2014
GR26.03.2014
CH31.03.2014
LI31.03.2014
IS25.04.2014
PT28.04.2014
Former [2016/27]AT25.12.2013
BE25.12.2013
BG25.12.2013
CY25.12.2013
CZ25.12.2013
DK25.12.2013
EE25.12.2013
ES25.12.2013
FI25.12.2013
LT25.12.2013
LV25.12.2013
MC25.12.2013
MT25.12.2013
NL25.12.2013
PL25.12.2013
RO25.12.2013
SE25.12.2013
SI25.12.2013
SK25.12.2013
LU06.03.2014
CH31.03.2014
LI31.03.2014
IS25.04.2014
PT28.04.2014
Former [2016/25]AT25.12.2013
BE25.12.2013
BG25.12.2013
CY25.12.2013
CZ25.12.2013
DK25.12.2013
EE25.12.2013
ES25.12.2013
FI25.12.2013
LT25.12.2013
LV25.12.2013
MT25.12.2013
NL25.12.2013
PL25.12.2013
RO25.12.2013
SE25.12.2013
SI25.12.2013
SK25.12.2013
LU06.03.2014
CH31.03.2014
LI31.03.2014
IS25.04.2014
PT28.04.2014
Former [2016/12]AT25.12.2013
BE25.12.2013
CY25.12.2013
CZ25.12.2013
DK25.12.2013
EE25.12.2013
ES25.12.2013
FI25.12.2013
LT25.12.2013
LV25.12.2013
MT25.12.2013
NL25.12.2013
PL25.12.2013
RO25.12.2013
SE25.12.2013
SI25.12.2013
SK25.12.2013
LU06.03.2014
CH31.03.2014
LI31.03.2014
IS25.04.2014
PT28.04.2014
Former [2016/07]AT25.12.2013
BE25.12.2013
CY25.12.2013
CZ25.12.2013
DK25.12.2013
EE25.12.2013
ES25.12.2013
FI25.12.2013
LT25.12.2013
LV25.12.2013
NL25.12.2013
PL25.12.2013
RO25.12.2013
SE25.12.2013
SI25.12.2013
SK25.12.2013
LU06.03.2014
CH31.03.2014
LI31.03.2014
IS25.04.2014
PT28.04.2014
Former [2015/24]AT25.12.2013
BE25.12.2013
CY25.12.2013
CZ25.12.2013
DK25.12.2013
EE25.12.2013
ES25.12.2013
FI25.12.2013
LT25.12.2013
LV25.12.2013
NL25.12.2013
PL25.12.2013
RO25.12.2013
SE25.12.2013
SI25.12.2013
SK25.12.2013
IE06.03.2014
LU06.03.2014
CH31.03.2014
LI31.03.2014
IS25.04.2014
PT28.04.2014
Former [2015/08]AT25.12.2013
BE25.12.2013
CY25.12.2013
CZ25.12.2013
DK25.12.2013
EE25.12.2013
ES25.12.2013
FI25.12.2013
LT25.12.2013
LV25.12.2013
NL25.12.2013
PL25.12.2013
RO25.12.2013
SE25.12.2013
SK25.12.2013
IE06.03.2014
LU06.03.2014
CH31.03.2014
LI31.03.2014
IS25.04.2014
PT28.04.2014
Former [2015/07]AT25.12.2013
BE25.12.2013
CY25.12.2013
CZ25.12.2013
DK25.12.2013
EE25.12.2013
ES25.12.2013
FI25.12.2013
LT25.12.2013
LV25.12.2013
NL25.12.2013
PL25.12.2013
RO25.12.2013
SE25.12.2013
SK25.12.2013
IE06.03.2014
LU06.03.2014
IS25.04.2014
PT28.04.2014
Former [2014/48]AT25.12.2013
BE25.12.2013
CY25.12.2013
CZ25.12.2013
DK25.12.2013
EE25.12.2013
ES25.12.2013
FI25.12.2013
LT25.12.2013
LV25.12.2013
NL25.12.2013
PL25.12.2013
RO25.12.2013
SE25.12.2013
SK25.12.2013
LU06.03.2014
IS25.04.2014
PT28.04.2014
Former [2014/39]AT25.12.2013
BE25.12.2013
CY25.12.2013
CZ25.12.2013
EE25.12.2013
ES25.12.2013
FI25.12.2013
LT25.12.2013
LV25.12.2013
NL25.12.2013
PL25.12.2013
RO25.12.2013
SE25.12.2013
SK25.12.2013
IS25.04.2014
PT28.04.2014
Former [2014/37]AT25.12.2013
BE25.12.2013
CY25.12.2013
CZ25.12.2013
EE25.12.2013
ES25.12.2013
FI25.12.2013
LT25.12.2013
LV25.12.2013
PL25.12.2013
RO25.12.2013
SE25.12.2013
SK25.12.2013
IS25.04.2014
PT28.04.2014
Former [2014/36]BE25.12.2013
EE25.12.2013
FI25.12.2013
LT25.12.2013
LV25.12.2013
SE25.12.2013
IS25.04.2014
Former [2014/34]BE25.12.2013
FI25.12.2013
LT25.12.2013
LV25.12.2013
SE25.12.2013
Former [2014/25]FI25.12.2013
LT25.12.2013
LV25.12.2013
SE25.12.2013
Former [2014/22]FI25.12.2013
LT25.12.2013
SE25.12.2013
Former [2014/20]LT25.12.2013
Documents cited:Search[I]WO9427638  (DANA FARBER CANCER INST INC [US]) [I] 1-26 * page 12, line 9 - page 13, line 15; claims 6-7; tables 2,3 *;
 WO03072736  [ ] (UNIV DUKE [US], et al);
 [IY]US2003202975  (TEDDER THOMAS F [US]) [I] 1-26 * paragraph [0157]; example 2; claims 1-38 * [Y] 1-26;
 [Y]WO03093320  (CELLTECH R&D LTD [GB], et al) [Y] 1-26* example 2; claims 1-45 *;
 [I]US2004001828  (TUSCANO JOSEPH [US], et al) [I] 1-26 * example 2; claims 1-37 *;
 [A]US2005118182  (PASTAN IRA H [US], et al) [A] 1-26 * claims 1-44 *;
 [T]WO2007103470  (MEDIMMUNE INC [US], et al) [T] * the whole document *;
 [ID]  - TUSCANO JOSEPH M ET AL, "Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts.", BLOOD 1 MAY 2003, (20030501), vol. 101, no. 9, ISSN 0006-4971, pages 3641 - 3647, XP002540281 [ID] 1-26 * page 3642, column left, paragraph last; figures 2,3; table 2 *

DOI:   http://dx.doi.org/10.1182/blood-2002-08-2629
 [T]  - O'DONNELL ROBERT T ET AL, "Treatment of non-Hodgkin's lymphoma xenografts with the HB22.7 anti-CD22 monoclonal antibody and phosphatase inhibitors improves efficacy.", CANCER IMMUNOLOGY, IMMUNOTHERAPY : CII OCT 2009, (200910), vol. 58, no. 10, ISSN 1432-0851, pages 1715 - 1722, XP002540282 [T] * the whole document *

DOI:   http://dx.doi.org/10.1007/s00262-009-0688-5
 [I]  - ENGEL P ET AL, "THE SAME EPITOPE ON CD22 OF LYMPHOCYTES MEDIATES THE ADHESION OF ERYTHROCYTES, T AND B LYMPHOCYTES, NEUTROPHILS, AND MONOCYTES", JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, (19930601), vol. 150, no. 11, ISSN 0022-1767, pages 4719 - 4732, XP000999233 [I] 1-26 * page 4720, paragraph last - column right, paragraph 1 * * page 4723, column r, paragraph 3 - page 4725, column r, paragraph 1; tables 1,2 *
International search[A]US2004001828  (TUSCANO JOSEPH [US], et al);
 [A]  - ENGEL P. ET AL., "IDENTIFICATION OF THE LIGAND-BINDING DORMAINS OF CD22, A MEMBER OF THE IMMUNOGLOBULIN SUPERFAMILY THAT UNIQUELY BINDS A SIALIC ACID-DEPENDENT LIGAND", J. EXP. MED., (19950401), vol. 181, no. 4, pages 1581 - 1586, XP001005276

DOI:   http://dx.doi.org/10.1084/jem.181.4.1581
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.